TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia

Norinaga Urahama, Ryuji Tanosaki, Kami Masahiro, Kimiko Iijima, Aki Chizuka, Sung Won Kim, Akiko Hori, Rie Kojima, Osamu Imataki, Atsushi Makimito, Shin Mineishi, Yoichi Takaue

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND: TRALI is one of the most serious, life-threatening complications after blood transfusion. Antibodies against neutrophils or HLA molecules from the donor are thought to be the primary causative agents. Rarely, antibodies in the recipient may react with transfused neutrophils and initiate the same events, which raises the possibility that TRALI may also occur in an allogeneic PBPC transplantation setting. CASE REPORT: A 30-year-old Japanese man with acute lymphoblastic leukemia developed TRALI immediately after the infusion of marrow cells from an unrelated donor. The infusion was suspended, and he gradually improved after receiving steroids and oxygen support. The next day, the remaining cells, which were separated to MNCs, were infused with no reactions. He then recovered over 5 days without the use of mechanical ventilation. RESULTS: Laboratory evaluation disclosed the presence of antibodies to neutrophils in his sera sampled after transplantation, but not in the donor's marrow graft. Hence, antibodies to neutrophils in the recipient may have reacted with neutrophils in the graft and contributed to the development of TRALI. CONCLUSION: This is the first reported case of TRALI after allogeneic BMT. TRALI should be recognized as a rare but serious complication in allogeneic hematopoietic stem cell transplantation.

Original languageEnglish (US)
Pages (from-to)1553-1557
Number of pages5
JournalTransfusion
Volume43
Issue number11
DOIs
StatePublished - Nov 1 2003

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neutrophils
Bone Marrow
Antibodies
Tissue Donors
Transplants
Unrelated Donors
Hematopoietic Stem Cell Transplantation
Homologous Transplantation
Artificial Respiration
Blood Transfusion
Transplantation
Steroids
Oxygen
Serum

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Hematology

Cite this

Urahama, N., Tanosaki, R., Masahiro, K., Iijima, K., Chizuka, A., Kim, S. W., ... Takaue, Y. (2003). TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia. Transfusion, 43(11), 1553-1557. https://doi.org/10.1046/j.1537-2995.2003.00542.x
Urahama, Norinaga ; Tanosaki, Ryuji ; Masahiro, Kami ; Iijima, Kimiko ; Chizuka, Aki ; Kim, Sung Won ; Hori, Akiko ; Kojima, Rie ; Imataki, Osamu ; Makimito, Atsushi ; Mineishi, Shin ; Takaue, Yoichi. / TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia. In: Transfusion. 2003 ; Vol. 43, No. 11. pp. 1553-1557.
@article{b05dca01f8474a679e8b23f8c3d4b5f7,
title = "TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia",
abstract = "BACKGROUND: TRALI is one of the most serious, life-threatening complications after blood transfusion. Antibodies against neutrophils or HLA molecules from the donor are thought to be the primary causative agents. Rarely, antibodies in the recipient may react with transfused neutrophils and initiate the same events, which raises the possibility that TRALI may also occur in an allogeneic PBPC transplantation setting. CASE REPORT: A 30-year-old Japanese man with acute lymphoblastic leukemia developed TRALI immediately after the infusion of marrow cells from an unrelated donor. The infusion was suspended, and he gradually improved after receiving steroids and oxygen support. The next day, the remaining cells, which were separated to MNCs, were infused with no reactions. He then recovered over 5 days without the use of mechanical ventilation. RESULTS: Laboratory evaluation disclosed the presence of antibodies to neutrophils in his sera sampled after transplantation, but not in the donor's marrow graft. Hence, antibodies to neutrophils in the recipient may have reacted with neutrophils in the graft and contributed to the development of TRALI. CONCLUSION: This is the first reported case of TRALI after allogeneic BMT. TRALI should be recognized as a rare but serious complication in allogeneic hematopoietic stem cell transplantation.",
author = "Norinaga Urahama and Ryuji Tanosaki and Kami Masahiro and Kimiko Iijima and Aki Chizuka and Kim, {Sung Won} and Akiko Hori and Rie Kojima and Osamu Imataki and Atsushi Makimito and Shin Mineishi and Yoichi Takaue",
year = "2003",
month = "11",
day = "1",
doi = "10.1046/j.1537-2995.2003.00542.x",
language = "English (US)",
volume = "43",
pages = "1553--1557",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "11",

}

Urahama, N, Tanosaki, R, Masahiro, K, Iijima, K, Chizuka, A, Kim, SW, Hori, A, Kojima, R, Imataki, O, Makimito, A, Mineishi, S & Takaue, Y 2003, 'TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia', Transfusion, vol. 43, no. 11, pp. 1553-1557. https://doi.org/10.1046/j.1537-2995.2003.00542.x

TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia. / Urahama, Norinaga; Tanosaki, Ryuji; Masahiro, Kami; Iijima, Kimiko; Chizuka, Aki; Kim, Sung Won; Hori, Akiko; Kojima, Rie; Imataki, Osamu; Makimito, Atsushi; Mineishi, Shin; Takaue, Yoichi.

In: Transfusion, Vol. 43, No. 11, 01.11.2003, p. 1553-1557.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia

AU - Urahama, Norinaga

AU - Tanosaki, Ryuji

AU - Masahiro, Kami

AU - Iijima, Kimiko

AU - Chizuka, Aki

AU - Kim, Sung Won

AU - Hori, Akiko

AU - Kojima, Rie

AU - Imataki, Osamu

AU - Makimito, Atsushi

AU - Mineishi, Shin

AU - Takaue, Yoichi

PY - 2003/11/1

Y1 - 2003/11/1

N2 - BACKGROUND: TRALI is one of the most serious, life-threatening complications after blood transfusion. Antibodies against neutrophils or HLA molecules from the donor are thought to be the primary causative agents. Rarely, antibodies in the recipient may react with transfused neutrophils and initiate the same events, which raises the possibility that TRALI may also occur in an allogeneic PBPC transplantation setting. CASE REPORT: A 30-year-old Japanese man with acute lymphoblastic leukemia developed TRALI immediately after the infusion of marrow cells from an unrelated donor. The infusion was suspended, and he gradually improved after receiving steroids and oxygen support. The next day, the remaining cells, which were separated to MNCs, were infused with no reactions. He then recovered over 5 days without the use of mechanical ventilation. RESULTS: Laboratory evaluation disclosed the presence of antibodies to neutrophils in his sera sampled after transplantation, but not in the donor's marrow graft. Hence, antibodies to neutrophils in the recipient may have reacted with neutrophils in the graft and contributed to the development of TRALI. CONCLUSION: This is the first reported case of TRALI after allogeneic BMT. TRALI should be recognized as a rare but serious complication in allogeneic hematopoietic stem cell transplantation.

AB - BACKGROUND: TRALI is one of the most serious, life-threatening complications after blood transfusion. Antibodies against neutrophils or HLA molecules from the donor are thought to be the primary causative agents. Rarely, antibodies in the recipient may react with transfused neutrophils and initiate the same events, which raises the possibility that TRALI may also occur in an allogeneic PBPC transplantation setting. CASE REPORT: A 30-year-old Japanese man with acute lymphoblastic leukemia developed TRALI immediately after the infusion of marrow cells from an unrelated donor. The infusion was suspended, and he gradually improved after receiving steroids and oxygen support. The next day, the remaining cells, which were separated to MNCs, were infused with no reactions. He then recovered over 5 days without the use of mechanical ventilation. RESULTS: Laboratory evaluation disclosed the presence of antibodies to neutrophils in his sera sampled after transplantation, but not in the donor's marrow graft. Hence, antibodies to neutrophils in the recipient may have reacted with neutrophils in the graft and contributed to the development of TRALI. CONCLUSION: This is the first reported case of TRALI after allogeneic BMT. TRALI should be recognized as a rare but serious complication in allogeneic hematopoietic stem cell transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0242523656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242523656&partnerID=8YFLogxK

U2 - 10.1046/j.1537-2995.2003.00542.x

DO - 10.1046/j.1537-2995.2003.00542.x

M3 - Article

C2 - 14617314

AN - SCOPUS:0242523656

VL - 43

SP - 1553

EP - 1557

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 11

ER -

Urahama N, Tanosaki R, Masahiro K, Iijima K, Chizuka A, Kim SW et al. TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia. Transfusion. 2003 Nov 1;43(11):1553-1557. https://doi.org/10.1046/j.1537-2995.2003.00542.x